Clinical trial
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B…
NCT00035789 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00035789 |
|---|---|
| Title | A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Entecavir |
| Start date | Nov 1, 2001 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | May 6, 2002 |
| Last update posted | Apr 14, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: